Hyman, Phelps & McNamara Enters its 45th Year Continuing to Expand its Capabilities to Meet Client Needs
FDA Law Blog: Biosimilars
APRIL 6, 2025
Hyman, Phelps & McNamara (HPM) marks its 45thAnniversary year by welcoming three accomplished professionals who reinforce the depth and breadth of the firms FDA and DEA practices. Naomi Lowy joins HPM as a Principal Drug Regulatory Expert after 18 years at the FDAs Center for Drug Evaluation and Research (CDER), most recently as the Deputy Director, Division of General Endocrinology.
Let's personalize your content